The Shanghai Government has placed an order with Sinovac Biotech to supply its inactivated hepatitis A vaccine, Healive, to be distributed in the city’s public markets.
The vaccine order, valued at approximately $3m, was awarded solely to Sinovac which outcompeted five other vaccine manufacturers for the contract.
Sinovac chairman, president and CEO Weidong Yin said that earlier this year, the company established growth for Healive in the public and private pay markets as a strategic goal.
“We have done just that, securing large Healive purchase orders from the Shanghai Government and China’s Ministry of Public Health,” Yin said.
The contract to supply the vaccine will run for 12 months and is part of the national expanded immunisation programme funded by the Chinese Government.